Cigarette smoking, cyclooxygenase-2 pathway and cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1815, Issue 2, 2011, Pages 158-169

  Huang, Run Yue ^a   Chen, George G ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer; Cigarette smoking; Cyclooxygenase; Nicotine; NNK; Prostacyclin; Prostaglandin E2; Thromboxane A2

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FUREGRELATE; NICOTINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROSTACYCLIN; PROSTAGLANDIN E2; THROMBOXANE A2; THROMBOXANE SYNTHASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER GROWTH; CARCINOGENESIS; CIGARETTE SMOKING; DIGESTIVE SYSTEM CANCER; ENZYME ACTIVITY; ENZYME INDUCTION; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE DEFICIENCY; INFLAMMATION; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR INTERACTION; MUSCLE FIBER CONTRACTION; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THROMBOCYTE ACTIVATION; TREATMENT PLANNING; TUMOR VASCULARIZATION;

ANIMALS; CYCLOOXYGENASE 2; HUMANS; NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; SMOKING;

EID: 78651347917     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.11.005     Document Type: Review

References (212)

1. Jha P. Avoidable global cancer deaths and total deaths from smoking. Nat. Rev. Cancer 2009, 9:655-664.
2. Stämpfli M.R., Anderson G.P. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat. Rev. Immunol. 2009, 9:377-384.
3. Shin V.Y., Cho C.H. Nicotine and gastric cancer. Alcohol 2005, 35:259-264.
4. Hecht S.S. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat. Rev. Cancer 2003, 3:733-744.
5. Shah K.A., Karnes H.T. A review of the analysis of tobacco-specific nitrosamines in biological matrices. Crit. Rev. Toxicol. 2010, 40:305-327.
6. Prokopczyk B., Hoffmann D., Bologna M., Cunningham A.J., Trushin N., Akerkar S., Boyiri T., Amin S., Desai D., Colosimo S., Pittman B., Leder G., Ramadani M., Henne-Bruns D., Beger H.G., El-Bayoumy K. Identification of tobacco-derived compounds in human pancreatic juice. Chem. Res. Toxicol. 2002, 15:677-685.
7. Hecht S.S., Rivenson A., Braley J., DiBello J., Adams J.D., Hoffmann D. Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Res. 1986, 46:4162-4166.
8. Chen C., Cook L.S., Li X.Y., Hallagan S., Madeleine M.M., Daling J.R., Weiss N.S. CYP2D6 genotype and the incidence of anal and vulvar cancer. Cancer Epidemiol. Biomark. Prev. 1999, 8:317-321.
9. Siriwardhana N., Choudhary S., Wang H.C. Precancerous model of human breast epithelial cells induced by NNK for prevention. Breast Cancer Res. Treat. 2008, 109:427-441. Electronic publisher 2007 Jul 26.
10. Prokopczyk B., Sinha I., Trushin N., Freeman W.M., El-Bayoumy K. Gene expression profiles in HPV-immortalized human cervical cells treated with the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Chem. Biol. Interact. 2009, 177:173-180. Electronic publisher 2008 Nov 6.
11. Pulling L.C., Klinge D.M., Belinsky S.A. p16INK4a and beta-catenin alterations in rat liver tumors induced by NNK. Carcinogenesis 2001, 22:461-466.
12. Shin V.Y., Jin H.C., Ng E.K., Yu J., Leung W.K., Cho C.H., Sung J.J. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: involvement of nicotinic acetylcholine receptor (nAChR) and beta-adrenergic receptor signaling pathways. Toxicol. Appl. Pharmacol. 2008, 233:254-261.
13. Smith T.J., Liao A., Wang L.D., Yang G.Y., Starcic S., Philbert M.A., Yang C.S. Characterization of xenobiotic-metabolizing enzymes and nitrosamine metabolism in the human esophagus. Carcinogenesis 1998, 19:667-672.
14. Wu W.K., Wong H.P., Luo S.W., Chan K., Huang F.Y., Hui M.K., Lam E.K., Shin V.Y., Ye Y.N., Yang Y.H., Cho C.H. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone from cigarette smoke stimulates colon cancer growth via beta-adrenoceptors. Cancer Res. 2005, 65:5272-5277.
15. Yoo G.H., Washington J., Piechocki M., Ensley J., Shibuya T., Oda D., Wei W.Z. Progression of head and neck cancer in an in vitro model. Arch. Otolaryngol. Head Neck Surg. 2000, 126:1313-1318.
16. Mathison B.H., Harman A.E., Bogdanffy M.S. DNA damage in the nasal passageway: a literature review. Mutat. Res. 1997, 380:77-96.
17. Watanabe K.H., Djordjevic M.V., Stellman S.D., Toccalino P.L., Austin D.F., Pankow J.F. Incremental lifetime cancer risks computed for benzo[a]pyrene and two tobacco-specific N-nitrosamines in mainstream cigarette smoke compared with lung cancer risks derived from epidemiologic data. Regul. Toxicol. Pharmacol. 2009, 55:123-133. Electronic publisher 2009 Jun 18.
18. Adwan H., Bäuerle T.J., Berger M.R. Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther. 2004, 11:109-120.
19. Binato M., Kruel Schmidt M., Silveira Volkweis B., Behrend Silva Ribeiro G., Isabel Edelweiss M., Ricachenevsky Gurski R. Mouse model of diethylnitrosamine-induced gastric cancer. J. Surg. Res. 2008, 148:152-157. Electronic publisher 2008 Jan 10.
20. Gurski R.R., Schirmer C.C., Kruel C.R., Komlos F., Kruel C.D., Edelweiss M.I. Induction of esophageal carcinogenesis by diethylnitrosamine and assessment of the promoting effect of ethanol and N-nitrosonornicotine: experimental model in mice. Dis. Esophagus 1999, 12:99-105.
21. Murphy S.E., Isaac I.S., Ding X., McIntee E.J. Specificity of cytochrome P450 2A3-catalyzed alpha-hydroxylation of N'-nitrosonornicotine enantiomers. Drug Metab. Dispos. 2000, 28:1263-1266.
22. Alam S., Conway M.J., Chen H.S., Meyers C. The cigarette smoke carcinogen benzo[a]pyrene enhances human papillomavirus synthesis. J. Virol. 2008, 82:1053-1058. Electronic publication 2007 Nov 7.
23. Kuramoto M., Sakata Y., Terai K., Kawasaki I., Kunitomo J., Ohishi T., Yokomizo T., Takeda S., Tanaka S., Ohishi Y. Preparation of leukotriene B(4) inhibitory active 2- and 3-(2-aminothiazol-4-yl)benzo[b]furan derivatives and their growth inhibitory activity on human pancreatic cancer cells. Org. Biomol. Chem. 2008, 6:2772-2781. Electronic publication 2008 May 29.
24. Borza A., Plöttner S., Wolf A., Behm C., Selinski S., Hengstler J.G., Roos P.H., Bolt H.M., Kuhlmann J., Föllmann W. Synergism of aromatic amines and benzo[a]pyrene in induction of Ah receptor-dependent genes. Arch. Toxicol. 2008, 82:973-980. Electronic publication 2008 Nov 7.
25. Gorlewska-Roberts K., Green B., Fares M., Ambrosone C.B., Kadlubar F.F. Carcinogen-DNA adducts in human breast epithelial cells. Environ. Mol. Mutagen. 2002, 39:184-192.
26. Azuine M.A., Bhide S.V. Adjuvant chemoprevention of experimental cancer: catechin and dietary turmeric in forestomach and oral cancer models. J. Ethnopharmacol. 1994, 44:211-217.
27. Costa C., Catania S., De Pasquale R., Stancanelli R., Scribano G.M., Melchini A. Exposure of human skin to benzo[a]pyrene: role of CYP1A1 and aryl hydrocarbon receptor in oxidative stress generation. Toxicology 2010, 271:83-86. Electronic publication 2010 Mar 20.
28. Bonnesen C., Eggleston I.M., Hayes J.D. Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. Cancer Res. 2001, 61:6120-6130.
29. Chen J., Yan Y., Li J., Ma Q., Stoner G.D., Ye J., Huang C. Differential requirement of signal pathways for benzo[a]pyrene (B[a]P)-induced nitric oxide synthase (iNOS) in rat esophageal epithelial cells. Carcinogenesis 2005, 26:1035-1043. Electronic publication 2005 Feb 17.
30. Dock L., Scheu G., Jernström B., Martinez M., Torndal U.B., Eriksson L. Benzo[a]pyrene metabolism and induction of enzyme-altered foci in regenerating rat liver. Chem. Biol. Interact. 1988, 67:243-253.
31. Egeli U., Ozkan L., Tunca B., Kahraman S., Ceçener G., Ergül E., Engin K. The relationship between genetic susceptibility to head and neck cancer with the expression of common fragile sites. Head Neck 2000, 22:591-598.
32. Gajecka M., Rydzanicz M., Jaskula-Sztul R., Wierzbicka M., Szyfter W., Szyfter K. Reduced DNA repair capacity in laryngeal cancer subjects. A comparison of phenotypic and genotypic results. Adv. Otorhinolaryngol. 2005, 62:25-37.
33. Hrubá E., Trilecová L., Marvanová S., Krcmár P., Vykopalová L., Milcová A., Líbalová H., Topinka J., Starsíchová A., Soucek K., Vondrácek J., Machala M. Genotoxic polycyclic aromatic hydrocarbons fail to induce the p53-dependent DNA damage response, apoptosis or cell-cycle arrest in human prostate carcinoma LNCaP cells. Toxicol. Lett. 2010, 197:227-235. Electronic publication 2010 Jun 11.
34. Kim J.Y., Chung J.Y., Park J.E., Lee S.G., Kim Y.J., Cha M.S., Han M.S., Lee H.J., Yoo Y.H., Kim J.M. Benzo[a]pyrene induces apoptosis in RL95-2 human endometrial cancer cells by cytochrome P450 1A1 activation. Endocrinology 2007, 148:5112-5122. Electronic publisher 2007 Jul 19.
35. Hix C., Oglesby L., MacNair P., Sieg M., Langenbach R. Bovine bladder and liver cell and homogenate-mediated mutagenesis of Salmonella typhimurium with aromatic amines. Carcinogenesis 1983, 4:1401-1407.
36. Hein D.W., Doll M.A., Gray K., Rustan T.D., Ferguson R.J. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus. Cancer Res. 1993, 53:509-514.
37. Saletta F., Matullo G., Manuguerra M., Arena S., Bardelli A., Vineis P. Exposure to the tobacco smoke constituent 4-aminobiphenyl induces chromosomal instability in human cancer cells. Cancer Res. 2007, 67:7088-7094.
38. Thompson P.A., Seyedi F., Lang N.P., MacLeod S.L., Wogan G.N., Anderson K.E., Tang Y.M., Coles B., Kadlubar F.F. Comparison of DNA adduct levels associated with exogenous and endogenous exposures in human pancreas in relation to metabolic genotype. Mutat. Res. 1999, 424:263-274.
39. Arif J.M., Dresler C., Clapper M.L., Gairola C.G., Srinivasan C., Lubet R.A., Gupta R.C. Lung DNA adducts detected in human smokers are unrelated to typical polyaromatic carcinogens. Chem. Res. Toxicol. 2006, 19:295-299.
40. Boccia S., Hashibe M., Gallì P., De Feo E., Asakage T., Hashimoto T., Hiraki A., Katoh T., Nomura T., Yokoyama A., van Duijn C.M., Ricciardi G., Boffetta P. Aldehyde dehydrogenase 2 and head and neck cancer: a meta-analysis implementing a Mendelian randomization approach. Cancer Epidemiol. Biomark. Prev. 2009, 18:248-254.
41. Homann N., Tillonen J., Meurman J.H., Rintamäki H., Lindqvist C., Rautio M., Jousimies-Somer H., Salaspuro M. Increased salivary acetaldehyde levels in heavy drinkers and smokers: a microbiological approach to oral cavity cancer. Carcinogenesis 2000, 21:663-668.
42. Toh Y., Oki E., Ohgaki K., Sakamoto Y., Ito S., Egashira A., Saeki H., Kakeji Y., Morita M., Sakaguchi Y., Okamura T., Maehara Y. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int. J. Clin. Oncol. 2010, 15:135-144. Electronic publisher 2010 Mar 12.
43. Salaspuro M. Acetaldehyde as a common denominator and cumulative carcinogen in digestive tract cancers. Scand. J. Gastroenterol. 2009, 44:912-925.
44. Seitz H.K., Cho C.H. Contribution of alcohol and tobacco use in gastrointestinal cancer development. Methods Mol. Biol. 2009, 472:217-241.
45. Bachand A.M., Mundt K.A., Mundt D.J., Montgomery R.R. Epidemiological studies of formaldehyde exposure and risk of leukemia and nasopharyngeal cancer: a meta-analysis. Crit. Rev. Toxicol. 2010, 40:85-100.
46. Berrino F., Richiardi L., Boffetta P., Estève J., Belletti I., Raymond L., Troschel L., Pisani P., Zubiri L., Ascunce N., Gubéran E., Tuyns A., Terracini B., Merletti F., Milan J.E.M. Occupation and larynx and hypopharynx cancer: a job-exposure matrix approach in an international case-control study in France, Italy, Spain and Switzerland. Cancer Causes Control 2003, 14:213-223. Working Group.
47. Burgaz S., Cakmak G., Erdem O., Yilmaz M., Karakaya A.E. Micronuclei frequencies in exfoliated nasal mucosa cells from pathology and anatomy laboratory workers exposed to formaldehyde. Neoplasma 2001, 48:144-147.
48. Piyathilake C.J., Bell W.C., Oelschlager D.K., Heimburger D.C., Grizzle W.E. The pattern of expression of Mn and Cu-Zn superoxide dismutase varies among squamous cell cancers of the lung, larynx, and oral cavity. Head Neck 2002, 24:859-867.
49. Bradbury B.D., Wilk J.B., Aschengrau A., Lash T.L. Departure from multiplicative interaction for catechol-O-methyltransferase genotype and active/passive exposure to tobacco smoke among women with breast cancer. J. Carcinog. 2006, 5:3.
50. Gopalakrishna R., Chen Z.H., Gundimeda U. Tobacco smoke tumor promoters, catechol and hydroquinone, induce oxidative regulation of protein kinase C and influence invasion and metastasis of lung carcinoma cells. Proc. Natl Acad. Sci. USA 1994, 91:12233-12237.
51. Bajtarevic A., Ager C., Pienz M., Klieber M., Schwarz K., Ligor M., Ligor T., Filipiak W., Denz H., Fiegl M., Hilbe W., Weiss W., Lukas P., Jamnig H., Hackl M., Haidenberger A., Buszewski B., Miekisch W., Schubert J., Amann A. Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer 2009, 9:348.
52. Hoffmann D., Melikian A.A., Wynder E.L. Scientific challenges in environmental carcinogenesis. Prev. Med. 1996, 25:14-22.
53. Mitra, A.K., Faruque, F.S., Avis, A.L., Breast cancer and environmental risks: where is the link? J Environ Health. 66 (2004) 24-32, 40; quiz 41-42.
54. Pesch B., Haerting J., Ranft U., Klimpel A., Oelschlägel B., Schill W. Occupational risk factors for renal cell carcinoma: agent-specific results from a case-control study in Germany. MURC Study Group. Multicenter urothelial and renal cancer study. Int. J. Epidemiol. 2000, 29:1014-1024.
55. Ketkar M.B., Haas H., Althoff J. Implantation of cigarette smoke condensate in the lungs of Syrian golden hamsters. J. Cancer Res. Clin. Oncol. 1979, 94:111-114.
56. Hecht S.S. Tobacco smoke carcinogens and breast cancer. Environ. Mol. Mutagen. 2002, 39:119-126.
57. Rego B. The Polonium brief: a hidden history of cancer, radiation, and the tobacco industry. Isis 2009, 100:453-484.
58. Amin S., Desai D., Hecht S.S., Hoffmann D. Synthesis of tobacco-specific N-nitrosamines and their metabolites and results of related bioassays. Crit. Rev. Toxicol. 1996, 26:139-147.
59. Djordjevic M.V., Doran K.A. Nicotine content and delivery across tobacco products. Handb. Exp. Pharmacol. 2009, 61-82.
60. Changeux J.P. Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat. Rev. Neurosci. 2010, 11:389-401.
61. Kelley D.J., Mestre J.R., Subbaramaiah K., Sacks P.G., Schantz S.P., Tanabe T., Inoue H., Ramonetti J.T., Dannenberg A.J. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 1997, 18:795-799.
62. Harizi H., Corcuff J.B., Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol. Med. 2008, 14:461-469.
63. Ristimäki A. Cyclooxygenase 2: from inflammation to carcinogenesis. Novartis Found. Symp. 2004, 256:215-221. discussion 221-226, 259-269.
64. Duffield-Lillico A.J., Boyle J.O., Zhou X.K., Ghosh A., Butala G.S., Subbaramaiah K., Newman R.A., Morrow J.D., Milne G.L., Dannenberg A.J. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev. Res. (Phila Pa) 2009, 2:322-329.
65. Anto R.J., Mukhopadhyay A., Shishodia S., Gairola C.G., Aggarwal B.B. Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2. Carcinogenesis 2002, 23:1511-1518.
66. Schuller H.M., Kabalka G., Smith G., Mereddy A., Akula M., Cekanova M. Detection of overexpressed COX-2 in precancerous lesions of hamster pancreas and lungs by molecular imaging: implications for early diagnosis and prevention. ChemMedChem 2006, 1:603-610.
67. Strillacci A., Griffoni C., Valerii M.C., Lazzarini G., Tomasi V., Spisni E. RNAi-based strategies for cyclooxygenase-2 inhibition in cancer. J. Biomed. Biotechnol. 2010, 2010:828045. Electronic publisher 2010 Jun 13.
68. Hastürk S., Kemp B., Kalapurakal S.K., Kurie J.M., Hong W.K., Lee J.S. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer 2002, 94:1023-1031.
69. Cathcart M.C., Reynolds J.V., O'Byrne K.J., Pidgeon G.P. The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. Biochim. Biophys. Acta 2010, 1805:153-166.
70. Smyth E.M., Grosser T., Wang M., Yu Y., FitzGerald G.A. Prostanoids in health and disease. J. Lipid Res. 2009, 50(Suppl):S423-S428.
71. Iniguez M.A., Cacheiro-Llaguno C., Cuesta N., Diaz-Munoz M.D., Fresno M. Prostanoid function and cardiovascular disease. Arch. Physiol. Biochem. 2008, 114:201-209.
72. Park J.Y., Pillinger M.H., Abramson S.B. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin. Immunol. 2006, 119:229-240.
73. Wilson D.P., Susnjar M., Kiss E., Sutherland C., Walsh M.P. Thromboxane A2-induced contraction of rat caudal arterial smooth muscle involves activation of Ca2+ entry and Ca2+ sensitization: Rho-associated kinase-mediated phosphorylation of MYPT1 at Thr-855, but not Thr-697. Biochem. J. 2005, 389:763-774.
74. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol. Ther. 2008, 118:18-35.
75. Félétou M., Vanhoutte P.M., Verbeuren T.J. The thromboxane/endoperoxide receptor (TP): the common villain. J. Cardiovasc. Pharmacol. 2010, 55:317-332.
76. Pradono P., Tazawa R., Maemondo M., Tanaka M., Usui K., Saijo Y., Hagiwara K., Nukiwa T. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 2002, 62:63-66.
77. Gryglewski R.J. Prostacyclin among prostanoids. Pharmacol. Rep. 2008, 60:3-11.
78. Wei J., Yan W., Li X., Chang W.C., Tai H.H. Activation of thromboxane receptor alpha induces expression of cyclooxygenase-2 through multiple signaling pathways in A549 human lung adenocarcinoma cells. Biochem. Pharmacol. 2007, 74:787-800.
79. Caughey G.E., Cleland L.G., Gamble J.R., James M.J. Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets. Role of thromboxane A2. J. Biol. Chem. 2001, 276:37839-37845.
80. Wang D., Dubois R.N. Prostaglandins and cancer. Gut 2006, 55:115-122.
81. Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J. Cell. Physiol. 2007, 213:589-602.
82. Hinz B., Brune K., Pahl A. Prostaglandin E(2) upregulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem. Biophys. Res. Commun. 2000, 16:744-748.
83. Minghetti L., Polazzi E., Nicolini A., Créminon C., Levi G. Up-regulation of cyclooxygenase-2 expression in cultured microglia by prostaglandin E2, cyclic AMP and non-steroidal anti-inflammatory drugs. Eur. J. Neurosci. 1997, 9:934-940.
84. Rösch S., Ramer R., Brune K., Hinz B. Prostaglandin E2 induces cyclooxygenase-2 expression in human non-pigmented ciliary epithelial cells through activation of p38 and p42/44 mitogen-activated protein kinases. Biochem. Biophys. Res. Commun. 2005, 338:1171-1178.
85. Wang M.T., Honn K.V., Nie D. Cyclooxygenases prostanoids, and tumor progression. Cancer Metastasis Rev. 2007, 26:525-534.
86. Martey C.A., Pollock S.J., Turner C.K., O'Reilly K.M., Baglole C.J., Phipps R.P., Sime P.J. Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 287:L981-L991.
87. Martey C.A., Baglole C.J., Gasiewicz T.A., Sime P.J., Phipps R.P. The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibroblasts. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 289:L391-L399.
88. Beloqui O., Páramo J.A., Orbe J., Benito A., Colina I., Monasterio A., Díez J. Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?. Eur. Heart J. 2005, 26:153-158.
89. Profita M., Sala A., Bonanno A., Riccobono L., Ferraro M., La Grutta S., Albano G.D., Montalbano A.M., Gjomarkaj M. Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 298:L261-L269.
90. Hwang D., Chanmugam P., Boudreau M., Sohn K.H., Stone K., Pryor W.A. Activation and inactivation of cyclo-oxygenase in rat alveolar macrophages by aqueous cigarette tar extracts. Free Radic. Biol. Med. 1999, 27:673-682.
91. Vassallo R., Kroening P.R., Parambil J., Kita H. Nicotine and oxidative cigarette smoke constituents induce immune-modulatory and pro-inflammatory dendritic cell responses. Mol. Immunol. 2008, 45:3321-3329.
92. McLemore T.L., Hubbard W.C., Litterst C.L., Liu M.C., Miller S., McMahon N.A., Eggleston J.C., Boyd M.R. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 1988, 48:3140-3147.
93. Chen G.G., Lee T.W., Yip J.H., Xu H., Lee I.K., Mok T.S., Warner T.D., Yim A.P. Increased thromboxane B(2) levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma. Cancer Lett. 2006, 234:193-198.
94. Badawi A.F., Habib S.L., Mohammed M.A., Abadi A.A., Michael M.S. Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer. Cancer Invest. 2002, 20:651-656.
95. Gross N.D., Boyle J.O., Morrow J.D., Williams M.K., Moskowitz C.S., Subbaramaiah K., Dannenberg A.J., Duffield-Lillico A.J. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin. Cancer Res. 2005, 11:6087-6093.
96. Greenhough A., Smartt H.J., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
97. Tian M., Schiemann W.P. PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. FASEB J. 2010, 24:1105-1116. Electronic publisher 2009 Nov 6.
98. Wang D., Dubois R.N. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010, 29:781-788. Electronic publisher 2009 Nov 30.
99. Kusmartsev S., Vieweg J. Enhancing the efficacy of cancer vaccines in urologic oncology: new directions. Nat. Rev. Urol. 2009, 6:540-549. Electronic publisher 2009 Sep 8.
100. Rångemark C., Ciabattoni G., Wennmalm A. Excretion of thromboxane metabolites in healthy women after cessation of smoking. Arterioscler. Thromb. 1993, 13:777-782.
101. Lee G., Walser T.C., Dubinett S.M. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr. Opin. Pulm. Med. 2009, 15:303-307.
102. Kuehl F.A., Egan R.W. Prostaglandins, arachidonic acid, and inflammation. Science 1980, 210:978-984.
103. Harris R.E. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacol. 2009, 17:55-67.
104. de Souza Pereira R. Selective cyclooxygenase-2 (COX-2) inhibitors used for preventing or regressing cancer. Recent Pat Anticancer Drug Discov. 2009, 4:157-163.
105. Mao J.T., Roth M.D., Serio K.J., Baratelli F., Zhu L., Holmes E.C., Strieter R.M., Dubinett S.M. Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. Clin. Cancer Res. 2003, 9:5835-5841.
106. Sugano N., Shimada K., Ito K., Murai S. Nicotine inhibits the production of inflammatory mediators in U937 cells through modulation of nuclear factor-kappaB activation. Biochem. Biophys. Res. Commun. 1998, 9:25-28.
107. Razani-Boroujerdi S., Sopori M.L. Early manifestations of NNK-induced lung cancer: role of lung immunity in tumor susceptibility. Am. J. Respir. Cell Mol. Biol. 2007, 36:13-19.
108. Takahashi H.K., Iwagaki H., Hamano R., Yoshino T., Tanaka N., Nishibori M. Effect of nicotine on IL-18-initiated immune response in human monocytes. J. Leukoc. Biol. 2006, 80:1388-1394.
109. Harris S.G., Padilla J., Koumas L., Ray D., Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol. 2002, 23:144-150.
110. Takahashi H.K., Iwagaki H., Hamano R., Kanke T., Liu K., Sadamori H., Yagi T., Yoshino T., Tanaka N., Nishibori M. The immunosuppressive effects of nicotine during human mixed lymphocyte reaction. Eur. J. Pharmacol. 2007, 559:69-74.
111. Granville C.A., Memmott R.M., Balogh A., Mariotti J., Kawabata S., Han W., Lopiccolo J., Foley J., Liewehr D.J., Steinberg S.M., Fowler D.H., Hollander M.C., Dennis P.A. A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. PLoS ONE 2009, 4:e5061.
112. Rioux N., Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. 1998, 58:5354-5360.
113. Warner J.H., Liang Q., Sarkar M., Mendes P.E., Roethig H.J. Adaptive regression modeling of biomarkers of potential harm in a population of U.S. adult cigarette smokers and nonsmokers. BMC Med. Res. Methodol. 2010, 16:19.
114. Lowe F.J., Gregg E.O., McEwan M. Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. Clin. Chem. Lab. Med. 2009, 47:311-320.
115. Calapai G., Caputi A.P., Mannucci C., Gregg E.O., Pieratti A., Aurora Russo G., Chaudhary N., Puntoni R., Lowe F., McEwan M., Bassi A., Morandi S., Nunziata A. A cross-sectional investigation of biomarkers of risk after a decade of smoking. Inhal. Toxicol. 2009, 21:1138-1143.
116. Wennmalm A., Benthin G., Granström E.F., Persson L., Petersson A.S., Winell S. Relation between tobacco consumption and urinary excretion of thromboxane A2 and prostacyclin metabolites in 756 randomly sampled young men. Adv. Prostaglandin Thromboxane Leukot. Res. 1991, 21B:615-618.
117. Dotevall A., Rångemark C., Eriksson E., Kutti J., Wadenvik H., Wennmalm A. Cigarette smoking increases thromboxane A2 formation without affecting platelet survival in young healthy females. Thromb. Haemost. 1992, 68:583-588.
118. Rångemark C., Benthin G., Granström E.F., Persson L., Winell S., Wennmalm A. Tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in women stratified by age. Circulation 1992, 86:1495-1500.
119. Wennmalm A., Benthin G., Granström E.F., Persson L., Winell S. Maintained hyperexcretion of thromboxane A2 metabolite in healthy young cigarette smokers: results from a prospective study in randomly sampled males with stable smoking habits. Clin. Physiol. 1993, 13:257-264.
120. Sherratt A.J., Culpepper B.T., Lubawy W.C. Alterations in prostacyclin and thromboxane formation following chronic exposure to high and low nicotine cigarettes in rats. Artery. 1987, 14:216-222.
121. Lubawy W.C., Culpepper B.T., Valentovic M.A. Alterations in prostacyclin and thromboxane formation by chronic cigarette smoke exposure: temporal relationships and whole smoke vs. gas phase. J. Appl. Toxicol. 1986, 6:77-80.
122. Wennmalm A. Effects of nicotine on cardiac prostaglandin and platelet thromboxane synthesis. Br. J. Pharmacol. 1978, 64:559-563.
123. Alster P., Wennmalm A. Effect of nicotine on the formation of prostacyclin-like activity and thromboxane in rabbit aorta and platelets. Br. J. Pharmacol. 1984, 81:55-60.
124. Wennmalm A., Alster P. Nicotine inhibits vascular prostacyclin but not platelet thromboxane formation. Gen. Pharmacol. 1983, 14:189-191.
125. Goerig M., Habenicht A.J. Effects of nicotine on eicosanoid synthesis of differentiating human promyelocytic leukemia cells. Klin. Wochenschr. 1988, 66(Suppl):117-119.
126. Goerig M., Ullrich V., Schettler G., Foltis C., Habenicht A. A new role for nicotine: selective inhibition of thromboxane formation by direct interaction with thromboxane synthase in human promyelocytic leukaemia cells differentiating into macrophages. Clin. Investig. 1992, 70:239-243.
127. Ringdahl B.E., Johnson G.K., Ali R.B., Organ C.C. Effect of nicotine on arachidonic acid metabolites and epithelial parameters in rat oral mucosa. J. Oral Pathol. Med. 1997, 26:40-45.
128. Lelcuk S., Threlfall L., Valeri C.R., Shepro D., Hechtman H.B. Nicotine stimulates pulmonary parenchymal thromboxane synthesis. Surgery 1986, 100:836-840.
129. Kihira Y., Kobayashi J., Kitamura S. Effects of nicotine and cigarette smoke extracts on plasma level of complement C3a and C5a, thromboxane B2 and 6-keto PGF1 alpha in rabbits. Nihon Kyobu Shikkan Gakkai Zasshi 1989, 27:1495-1501.
130. Hui S.C., Wang Z., Zhang H., Ogle C.W. Arachidonic acid metabolism in nicotine-treated rats and nicotine-incubated rabbit aortic smooth muscle cells. Clin. Exp. Pharmacol. Physiol. 1992, 19:689-693.
131. Uedelhoven W.M., Rützel A., Meese C.O., Weber P.C. Smoking alters thromboxane metabolism in man. Biochim. Biophys. Acta 1991, 1081:197-201.
132. Nowak J., Murray J.J., Oates J.A., FitzGerald G.A. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987, 76:6-14.
133. Shen R.F., Tai H.H. Monoclonal antibodies to thromboxane synthase from porcine lung. Production and application to development of a tandem immunoradiometric assay. J. Biol. Chem. 1986, 261:11585-11591.
134. McAdam B.F., Byrne D., Morrow J.D., Oates J.A. Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation 2005, 112:1024-1029.
135. Karim S., Habib A., Lévy-Toledano S., Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J. Biol. Chem. 1996, 271:12042-12048.
136. Tanizawa H., Iwanaga T., Tai H.H. Increase in thromboxane B2 and decrease in prostaglandin E2 and 6-keto-prostaglandin F1 alpha release into rat bronchoalveolar fluid as a consequence of cigarette smoking. Prostaglandins Leukot. Med. 1987, 28:195-201.
137. Matsumoto K., Aizawa H., Inoue H., Shigyo M., Takata S., Hara N. Thromboxane causes airway hyperresponsiveness after cigarette smoke-induced neurogenic inflammation. J. Appl. Physiol. 1996, 81:2358-2364.
138. Ermert L., Dierkes C., Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin. Cancer Res. 2003, 9:1604-1610.
139. Nie D., Che M., Zacharek A., Qiao Y., Li L., Li X., Lamberti M., Tang K., Cai Y., Guo Y., Grignon D., Honn K.V. Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am. J. Pathol. 2004, 164:429-439.
140. Cailleteau C., Liagre B., Battu S., Jayat-Vignoles C., Beneytout J.L. Increased cyclooxygenase-2 and thromboxane synthase expression is implicated in diosgenin-induced megakaryocytic differentiation in human erythroleukemia cells. Anal. Biochem. 2008, 380:26-34.
141. Sakai H., Suzuki T., Takahashi Y., Ukai M., Tauchi K., Fujii T., Horikawa N., Minamimura T., Tabuchi Y., Morii M., Tsukada K., Takeguchi N. Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. FEBS Lett. 2006, 580:3368-3374.
142. Nie D., Lamberti M., Zacharek A., Li L., Szekeres K., Tang K., Chen Y., Honn K.V. Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem. Biophys. Res. Commun. 2000, 267:245-251.
143. Moussa O., Riker J.M., Klein J., Fraig M., Halushka P.V., Watson D.K. Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. Oncogene 2008, 27:55-62.
144. Leung K.C., Hsin M.K., Chan J.S., Yip J.H., Li M., Leung B.C., Mok T.S., Warner T.D., Underwood M.J., Chen G.G. Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27. Exp. Cell Res. 2009, 315:2974-2981.
145. Watkins G., Douglas-Jones A., Mansel R.E., Jiang W.G. Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. Int. Semin. Surg. Oncol. 2005, 2:23.
146. Li X., Tai H.H. Activation of thromboxane A(2) receptors induces orphan nuclear receptor Nurr1 expression and stimulates cell proliferation in human lung cancer cells. Carcinogenesis 2009, 30:1606-1613.
147. Schauff A.K., Kim E.L., Leppert J., Nadrowitz R., Wuestenberg R., Brockmann M.A., Giese A. Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to gamma-radiation. J. Neurooncol. 2009, 91:241-249.
148. Dassesse T., de Leval X., de Leval L., Pirotte B., Castronovo V., Waltregny D. Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumor Gleason score and pathologic stage. Eur. Urol. 2006, 50:1021-1031.
149. Onguru O., Scheithauer B.W., Kovacs K., Vidal S., Jin L., Zhang S., Ruebel K.H., Lloyd R.V. Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas. Endocr. Pathol. 2004, 15:17-27.
150. Moussa O., Ashton A.W., Fraig M., Garrett-Mayer E., Ghoneim M.A., Halushka P.V., Watson D.K. Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Res. 2008, 68:4097-4104.
151. Kajita S., Ruebel K.H., Casey M.B., Nakamura N., Lloyd R.V. Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod. Pathol. 2005, 18:221-227.
152. Obara Y., Kurose H., Nakahata N. Thromboxane A2 promotes interleukin-6 biosynthesis mediated by an activation of cyclic AMP-response element-binding protein in 1321N1 human astrocytoma cells. Mol. Pharmacol. 2005, 68:670-679.
153. Sood S.L. Cancer-associated thrombosis. Curr. Opin. Hematol. 2009, 16:378-385.
154. Frisbee J.C., Goodwill A.G., Stapleton P.A., Frisbee S.J., d'Audiffret A.C. Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation. Physiol. Genomics 2010, 42:331-341.
155. Schmid P., Karanikas G., Kritz H., Pirich C., Stamatopoulos Y., Peskar B.A., Sinzinger H. Passive smoking and platelet thromboxane. Thromb. Res. 1996, 81:451-460.
156. Mehta P. Potential role of platelets in the pathogenesis of tumor metastasis. Blood 1984, 63:55-63.
157. Pacchiarini L., Zucchella M., Milanesi G., Tacconi F., Bonomi E., Canevari A., Grignani G. Thromboxane production by platelets during tumor cell-induced platelet activation. Invasion Metastasis 1991, 11:102-109.
158. Steinert B.W., Tang D.G., Grossi I.M., Umbarger L.A., Honn K.V. Studies on the role of platelet eicosanoid metabolism and integrin alpha IIb beta 3 in tumor-cell-induced platelet aggregation. Int. J. Cancer 1993, 54:92-101.
159. Honn K.V., Steinert B.W., Moin K., Onoda J.M., Taylor J.D., Sloane B.F. The role of platelet cyclooxygenase and lipoxygenase pathways in tumor cell induced platelet aggregation. Biochem. Biophys. Res. Commun. 1987, 145:384-389.
160. Grignani G., Pacchiarini L., Almasio P., Pagliarino M., Gamba G. Activation of platelet prostaglandin biosynthesis pathway during neoplastic cell-induced platelet aggregation. Thromb. Res. 1984, 34:147-157.
161. Kurahashi K., Shirahase H., Nakamura S., Tarumi T., Koshino Y., Wang A.M., Nishihashi T., Shimizu Y. Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and COX-1 metabolites. J. Cardiovasc. Pharmacol. 2001, 38(Suppl 1):S21-S25.
162. Holden W.E., Kishiyama S.S., Dong S.P., Osborne M.L. Endothelium-dependent effects of cigarette smoke components on tone of porcine intrapulmonary arteries in vitro. Toxicol. Appl. Pharmacol. 1990, 104:191-199.
163. Vanhoutte P.M., Shimokawa H., Tang E.H., Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol. (Oxf) 2009, 196:193-222.
164. Shirahase H., Usui H., Kurahashi K., Fujiwara M., Fukui K. Endothelium-dependent contraction induced by nicotine in isolated canine basilar artery-possible involvement of a thromboxane A2 (TXA2) like substance. Life Sci. 1988, 42:437-445.
165. Nie D., Guo Y., Yang D., Tang Y., Chen Y., Wang M.T., Zacharek A., Qiao Y., Che M., Honn K.V. Thromboxane A2 receptors in prostate carcinoma: expression and its role in regulating cell motility via small GTPase Rho. Cancer Res. 2008, 68:115-121.
166. Ji X., Nishihashi T., Trandafir C.C., Wang A., Shimizu Y., Kurahashi K. Pharmacological nature of nicotine-induced contraction in the rat basilar artery: involvement of arachidonic acid metabolites. Eur. J. Pharmacol. 2007, 577:109-114.
167. Hong J.L., Lee L.Y. Cigarette smoke-induced bronchoconstriction: causative agents and role of thromboxane receptors. J. Appl. Physiol. 1996, 81:2053-2059.
168. Zhang W., Zhang Y., Edvinsson L., Xu C.B. Up-regulation of thromboxane A2 receptor expression by lipid soluble smoking particles through post-transcriptional mechanisms. Atherosclerosis 2008, 196:608-616.
169. Xie Y.H., Wang S.W., Zhang Y., Edvinsson L., Xu C.B. Up-regulation of G-protein-coupled receptors for endothelin and thromboxane by lipid-soluble smoke particles in renal artery of rat. Basic Clin. Pharmacol. Toxicol. 2010, 107:803-812.
170. Daniel T.O., Liu H., Morrow J.D., Crews B.C., Marnett L.J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 1999, 59:4574-4577.
171. de Leval X., Dassesse T., Dogné J.M., Waltregny D., Bellahcène A., Benoit V., Pirotte B., Castronovo V. Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents. J. Pharmacol. Exp. Ther. 2006, 318:1057-1067.
172. Madsen H., Dyerberg J. Cigarette smoking and its effects on the platelet-vessel wall interaction. Scand J. Clin. Lab. Invest. 1984, 44:203-206.
173. Jeremy J.Y., Mikhailidis D.P., Dandona P. Cigarette smoke extracts, but not nicotine, inhibit prostacyclin (PGI2) synthesis in human, rabbit and rat vascular tissue. Prostaglandins Leukot. Med. 1985, 19:261-270.
174. Reinders J.H., Brinkman H.J., van Mourik J.A., deGroot P.G. Cigarette smoke impairs endothelial cell prostacyclin production. Arteriosclerosis 1986, 6:15-23.
175. Jeremy J.Y., Mikhailidis D.P., Dandona P. Cigarette smoke extracts inhibit prostacyclin synthesis by the rat urinary bladder. Br. J. Cancer 1985, 51:837-842.
176. Smith C.J., Fischer T.H., Heavner D.L., Rumple M.A., Bowman D.L., Brown B.G., Morton M.J., Doolittle D.J. Urinary thromboxane, prostacyclin, cortisol, and 8-hydroxy-2'-deoxyguanosine in nonsmokers exposed and not exposed to environmental tobacco smoke. Toxicol. Sci. 2001, 59:316-323.
177. Fedi P., Calabrò A., Orsini B., Milani S., Zacchi P., Salvadori G., Surrenti C. Cigarette smoking increases gastric luminal prostaglandin F2 alpha and thromboxane B2 in healthy smokers. Digestion 1990, 46:27-34.
178. Mehta P., Mehta J. Effects of smoking on platelets and on plasma thromboxane-prostacyclin balance in man. Prostaglandins Leukot. Med. 1982, 9:141-150.
179. Tai H.H., Chang W.C., Liu Y., Fukuda S. Alterations of arachidonate metabolism in cardiovascular system by cigarette smoking. Adv. Exp. Med. Biol. 1990, 273:211-224.
180. Rodrigues M., Havlik E., Peskar B., Sinzinger H. Prostaglandins as biochemical markers of radiation injury to the salivary glands after iodine-131 therapy?. Eur. J. Nucl. Med. 1998, 25:265-269.
181. Krzystyniak K.L. Current strategies for anticancer chemoprevention and chemoprotection. Acta Pol. Pharm. 2002, 59:473-478.
182. Saha D., Pyo H., Choy H. COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer. Am. J. Clin. Oncol. 2003, 26:S70-S74.
183. Marrogi A.J., Travis W.D., Welsh J.A., Khan M.A., Rahim H., Tazelaar H., Pairolero P., Trastek V., Jett J., Caporaso N.E., Liotta L.A., Harris C.C. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin. Cancer Res. 2000, 6:4739-4744.
184. Carpagnano G.E., Spanevello A., Palladino G.P., Gramiccioni C., Ruggieri C., Carpagnano F., Foschino Barbaro M.P. Cigarette smoke and increased COX-2 and survivin levels in exhaled breath condensate of lung cancer patients: how hot is the link?. Lung Cancer 2010, 67:108-113.
185. Yasui M., Yamamoto H., Ngan C.Y., Damdinsuren B., Sugita Y., Fukunaga H., Gu J., Maeda M., Takemasa I., Ikeda M., Fujio Y., Sekimoto M., Matsuura N., Weinstein I.B., Monden M. Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clin. Cancer Res. 2006, 12:4720-4729.
186. Bhoopathi P., Chetty C., Gujrati M., Dinh D.H., Rao J.S., Lakka S.S. The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine. Br. J. Cancer 2010, 102:530-540.
187. Shishodia S., Aggarwal B.B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res. 2004, 64:5004-5012.
188. Huang R.Y., Li M.Y., Hsin M.K., Underwood M.J., Ma L.T., Mok T.S., Warner T.D., Chen G.G. 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A(2) and its receptor. Oncogene 2010 Sep 6, Electronic publication ahead of print.
189. Umar Z.Y., Fleischer D.E. Esophageal cancer: epidemiology, pathogenesis and prevention. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008, 5:517-526.
190. Zong Y., Zhang S.T., Zhu S.T. Nicotine enhances migration and invasion of human esophageal squamous carcinoma cells which is inhibited by nimesulide. World J. Gastroenterol. 2009, 15:2500-2505.
191. Hermanova M., Trna J., Nenutil R., Dite P., Kala Z. Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions. Eur. J. Gastroenterol. Hepatol. 2008, 20:732-739.
192. Schuller H.M., Zhang L., Weddle D.L., Castonguay A., Walker K., Miller M.S. The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J. Cancer Res. Clin. Oncol. 2002, 128:525-532.
193. Shin V.Y., Wu W.K., Ye Y.N., So W.H., Koo M.W., Liu E.S., Luo J.C., Cho C.H. Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2. Carcinogenesis 2004, 25:2487-2495.
194. Shin V.Y., Wu W.K., Chu K.M., Wong H.P., Lam E.K., Tai E.K., Koo M.W., Cho C.H. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Mol. Cancer Res. 2005, 3:607-615.
195. Ye Y.N., Liu E.S., Shin V.Y., Wu W.K., Cho C.H. The modulating role of nuclear factor-kappaB in the action of alpha7-nicotinic acetylcholine receptor and cross-talk between 5-lipoxygenase and cyclooxygenase-2 in colon cancer growth induced by 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone. J. Pharmacol. Exp. Ther. 2004, 311:123-130.
196. Liu E.S., Shin V.Y., Ye Y.N., Luo J.C., Wu W.K., Cho C.H. Cyclooxygenase-2 in cancer cells and macrophages induces colon cancer cell growth by cigarette smoke extract. Eur. J. Pharmacol. 2005, 518:47-55.
197. Liu E.S., Ye Y.N., Shin V.Y., Wu W.K., Wong B.C., Cho C.H. Interaction of cigarette smoking with cyclooxygenase-2 on ulcerative colitis-associated neoplasia in mice. Cancer Invest. 2007, 25:750-757.
198. Wong H.P., Li Z.J., Shin V.Y., Tai E.K., Wu W.K., Yu L., Cho C.H. Effects of cigarette smoking and restraint stress on human colon tumor growth in mice. Digestion 2009, 80:209-214.
199. Kamat A.M., Sethi G., Aggarwal B.B. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol. Cancer Ther. 2007, 6:1022-1030.
200. Shishodia S., Potdar P., Gairola C.G., Aggarwal B.B. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 2003, 24:1269-1279.
201. Johnson J.T., Rabin B.S., Wagner R.L. Prostaglandin E2 of the upper aerodigestive tract. Ann. Otol. Rhinol. Laryngol. 1987, 96:213-216.
202. Kekatpure V.D., Boyle J.O., Zhou X.K., Duffield-Lillico A.J., Gross N.D., Lee N.Y., Subbaramaiah K., Morrow J.D., Milne G., Lippman S.M., Dannenberg A.J. Elevated levels of urinary prostaglandin E metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients. Cancer Prev. Res. (Phila Pa) 2009, 2:957-965.
203. Schuller H.M., Tithof P.K., Williams M., Plummer H. The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res. 1999, 59:4510-4515.
204. Wong H.P., Yu L., Lam E.K., Tai E.K., Wu W.K., Cho C.H. Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation. Toxicol. Sci. 2007, 97:279-287.
205. Weddle D.L., Tithoff P., Williams M., Schuller H.M. Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis 2001, 22:473-479.
206. Zhou Y., Wang Z.X., Tang M.P., Yao C.J., Xu W.J., Wang L.Y., Qiao Z.D. Nicotine induces cyclooxygenase-2 and prostaglandin E(2) expression in human umbilical vein endothelial cells. Int. Immunopharmacol. 2010, 10:461-466.
207. Nakao S., Ogata Y., Sugiya H. Nicotine stimulates the expression of cyclooxygenase-2 mRNA via NFkappaB activation in human gingival fibroblasts. Arch. Oral Biol. 2009, 54:251-257.
208. Moraitis D., Du B., De Lorenzo M.S., Boyle J.O., Weksler B.B., Cohen E.G., Carew J.F., Altorki N.K., Kopelovich L., Subbaramaiah K., Dannenberg A.J. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res. 2005, 65:664-670.
209. De Flora S., D'Agostini F., Balansky R., Camoirano A., Bennicelli C., Bagnasco M., Cartiglia C., Tampa E., Longobardi M.G., Lubet R.A., Izzotti A. Modulation of cigarette smoke-related end-points in mutagenesis and carcinogenesis. Mutat. Res. 2003, 523-524:237-252.
210. Tennis M.A., Vanscoyk M., Keith R.L., Winn R.A. The role of prostacyclin in lung cancer. Transl. Res. 2010, 155:57-61.
211. Li M.Y., Hsin M.K., Yip J., Mok T.S., Underwood M.J., Chen G.G. PPARgamma activation extinguishes smoking carcinogen by inhibiting NNK-mediated proliferation. Am. J. Respir. Cell Mol. Biol. 2010, 42:113-122.
212. Li M.Y., Yuan H., Ma L.T., Kong A.W., Hsin M.K., Yip J., Underwood M.J., Chen G.G. Roles of PPAR{alpha} and PPAR{gamma} in the development of non-small cell lung cancer. Am. J. Respir. Cell Mol. Biol. 2010, 43:674-683.